

Part VI: Summary of the risk management plan

Summary of risk management plan for Enalapril Accord 2.5 mg/ 5 mg/ 10 mg/ 20 mg tablets (Enalapril maleate)

This is a summary of the risk management plan (RMP) for Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets. The RMP details important risks of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets, how these risks can be minimised, and how more information will be obtained about Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets risks and uncertainties (missing information).

Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets RMP.

I. The medicine and what it is used for

Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets indicated for:

- Treatment of Hypertension.
- Treatment of Symptomatic Heart Failure.
- Prevention of Symptomatic Heart Failure in patients with Asymptomatic Left Ventricular Dysfunction (ejection fraction $\leq 35\%$).

It contains Enalapril maleate as the active substance and given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets, together with measures to minimise such risks and the proposed studies for learning more about Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

The data and conclusions included in this report are confidential and proprietary information of Marketing Authorization Holder.

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed including signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets is not yet available, it is listed under ‘missing information’ below.

II.A List of important risks and missing information

Important risks of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<p>Important identified risks</p>	<ul style="list-style-type: none"> • Angioneurotic oedema/Hypersensitivity • Renal function Impairment • Hypotension • Hyperkalaemia
-----------------------------------	--

	<ul style="list-style-type: none"> • Exposure during pregnancy • Cough • Hypoglycaemia
Important potential risks	<ul style="list-style-type: none"> • Use in patients with aortic stenosis/hypertrophic cardiomyopathy • Anaphylactoid reactions
Missing Information	<ul style="list-style-type: none"> • Use in nursing mothers • Use in paediatric populations • Use in hepatic impairment

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorization or specific obligation of Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Enalapril Accord 2.5 mg/ 5 mg/ 10 mg and 20 mg tablets as post-authorisation development plan.